Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

TD Cowen 45th Annual Health Care Conference on March 4 in Boston Leerink Partners Global Biopharma Conference on March 12 in ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

The FDA approved the sale of Zyn nicotine pouches, which are increasingly popular with teens. But nicotine pouches cause ...

Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven ...

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") will announce its full year results for the year ended 31 December 2024 on Thursday 27 February 2025 at 9:00 am Finnish time.

"We are pleased to present these data demonstrating cariprazine's potential to have an impact on patients as an adjunctive treatment of major depressive disorder ... to the FDA and further ...

Finding a successful treatment for neurological conditions such as Alzheimer’s Disease is a pressing need both in Australia ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...